Cardiovascular disease in type 2 diabetes mellitus: progress toward personalized management
Por:
Ma, CX, Ma, XN, Guan, CH, Li, YD, Mauricio, D, Fu, SB
Publicada:
14 may 2022
Resumen:
Cardiovascular diseases (CVDs) are the main cause of death among patients with type 2 diabetes mellitus (T2DM), particularly in low- and middle-income countries. To effectively prevent the development of CVDs in T2DM, considerable effort has been made to explore novel preventive approaches, individualized glycemic control and cardiovascular risk management (strict blood pressure and lipid control), together with recently developed glucose-lowering agents and lipid-lowering drugs. This review mainly addresses the important issues affecting the choice of antidiabetic agents and lipid, blood pressure and antiplatelet treatments considering the cardiovascular status of the patient. Finally, we also discuss the changes in therapy principles underlying CVDs in T2DM.
Filiaciones:
Ma, CX:
Lanzhou Univ, Hosp 1, Dept Endocrinol, 1 West Donggang Rd, Lanzhou 730000, Gansu, Peoples R China
Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China
Ma, XN:
Lanzhou Univ, Hosp 1, Dept Endocrinol, 1 West Donggang Rd, Lanzhou 730000, Gansu, Peoples R China
Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China
Guan, CH:
Lanzhou Univ, Hosp 1, Dept Endocrinol, 1 West Donggang Rd, Lanzhou 730000, Gansu, Peoples R China
Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China
Li, YD:
Gansu Univ Chinese Med, Coll Integrated Tradit Chinese & Western Med, Lanzhou 730000, Gansu, Peoples R China
Mauricio, D:
Autonomous Univ Barcelona, Hosp Santa Creu Sant Pau, Dept Endocrinol & Nutr, CIBER Diabet & Associated Metab Dis CIBERDEM, Barcelona 08041, Spain
Fu, SB:
Lanzhou Univ, Hosp 1, Dept Endocrinol, 1 West Donggang Rd, Lanzhou 730000, Gansu, Peoples R China
Lanzhou Univ, Clin Med Coll 1, Lanzhou 730000, Gansu, Peoples R China
gold, Green Published, Gold
|